(+)-JQ1

Catalog No.S7110

(+)-JQ1 Chemical Structure

Molecular Weight(MW): 456.99

(+)-JQ1 is a BET bromodomain inhibitor, with IC50 of 77 nM/33 nM for BRD4(1/2) in cell-free assays, binding to all bromodomains of the BET family, but not to bromodomains outside the BET family.

Size Price Stock Quantity  
USD 270 In stock
USD 570 In stock

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

3 Customer Reviews

  • The BET protein inhibitor JQ1 reduces c-Myc expression and attenuates primary MCC cell proliferation. A, decreased c-Myc expression in MCC-3 and MCC-5 treated with JQ1 (800 nmol/L) for 72 hours by qRT-PCR and immunoblotting. The mRNA expression of target genes was normalized to that of MRPS2 and a value of 1.0 was assigned to the mRNA expression of target genes in the control group (means+SEM; **, P < 0.01 vs. control); b-actin was used as a loading control for immunoblotting.

    Cancer Res 2014 74(23), 7090-102. (+)-JQ1 purchased from Selleck.

    Immunohistochemical staining of xenograft tumor tissues. Immunohistochemical staining of xenograft tumor tissues with the indicated antibodies. p21-, p27-, p57-, and Ki67 positive cells (brown staining) were quantified at x400 magnification (meansSEM;**, P < 0.01;***, P < 0.001 vs. control); scale bars, 10 um.

    Cancer Res 2014 74(23), 7090-102. (+)-JQ1 purchased from Selleck.

  • JQ1 induces cell cycle arrest and apoptosis in Cal27 cells. (C) Cal27 cells were treated with JQ1 for 24 h and whole cell lysates were tested by western blot assays for the expression of cleaved-caspase-3. GAPDH was used as a loading control. (D) Apoptosis of Cal27 cells treated with JQ1 at 0 and 0.5 µM JQ1; *P<0.05 vs. control (the DMSO group)

    Oncol Rep, 2016, 36(4):1989-96.. (+)-JQ1 purchased from Selleck.

Purity & Quality Control

Choose Selective Epigenetic Reader Domain Inhibitors

Click to view more

Notes:

2. For more details, such as half maximal inhibitory concentrations (IC50s) and working concentrations of each inhibitor, please click on the link of the inhibitor of interest.
3. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation.
4. Orange "√" refers to compounds which do inhibitory effects on the related isoform, but without specific value.

Biological Activity

Description (+)-JQ1 is a BET bromodomain inhibitor, with IC50 of 77 nM/33 nM for BRD4(1/2) in cell-free assays, binding to all bromodomains of the BET family, but not to bromodomains outside the BET family.
Features (+)-JQ1 is more effective than (-)-JQ1.
Targets
BRD4 (2) [1]
(Cell-free assay)
BRD4 (1) [1]
(Cell-free assay)
33 nM 77 nM
In vitro

(+)-JQ1 enantiomer binds directly into the Kac binding site of BET bromodomains. (+)-JQ1 (500 nM) binds BRD4 competitively with chromatin resulting in differentiation and growth arrest of NMC cells. (+)-JQ1 (500 nM) attenuates rapid proliferation of NMC 797 and Per403 cell lines as demonstrated by reduced Ki67 staining. (+)-JQ1 (500 nM) potently decreases expression of both BRD4 target genes in NMC 797 cells. (+)-JQ1 inhibits cellular viability with IC50 of 4 nM in NMC 11060 cells. [1] (+)-JQ1 results in robust inhibition of MYC expression in MM cell lines. (+)-JQ1 inhibits proliferating of KMS-34 and LR5 with IC50 of 68 nM and 98 nM, respectively. (+)-JQ1 (500 nM)-treated MM.1S cells results in a pronounced decrease in the proportion of cells in S-phase, with a concomitant increase in cells arrested in G0/G1. (+)-JQ1 (500 nM) results in pronounced cellular senescence by beta-galactosidase staining. (+)-JQ1 (800 nM) exposure leads to a significant reduction in cell viability among the majority of CD138+ patient-derived MM samples tested. [2] (+)-JQ1 inhibits growth of LP-1 cells with GI50 of 98 nM. (+)-JQ1 (625 nM) results in an increase in the percentage of LP-1 cells in G0/G1. (+)-JQ1 (500 nM) suppresses the expression of MYC, BRD4 and CDK9 in LP-1 cells. [3] (+)-JQ1 (1 μM) activates HIV transcription in latently infected Jurkat T cells. (+)-JQ1 (50 μM) stimulates predominantly Tat-dependent HIV transcription in both Jurkat and HeLa cells. (+)-JQ1 (5 μM) induces Brd4 dissociation enables Tat to recruit SEC to HIV promoter and induce Pol II CTD phosphorylation and viral transcription in J-Lat A2 cells. JQ1 enables Tat to increase CDK9 T-loop phosphorylation and partially dissociates P-TEFb from 7SK snRNP in Jurkat T cells. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
K1  M{PhT2NmdGxiVnnhZoltcXS7IFHzd4F6 NHLwN3gzPTBxNUCwM|ExODBibl2= MYmyOE81QC95MjDo NWLjRZBjTE2VTx?= MkfpbY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliaX6gZo91cCCmb4PlMUBidmRidHnt[U0h\GWyZX7k[Y51KG2jbn7ldi=> MkLjNlY4ODd6OEG=
BCPAP M1zMdmNmdGxiVnnhZoltcXS7IFHzd4F6 Mnv3NlUxNzVyMD:xNFAxKG6P M{L5NlI1NzR6L{eyJIg> MYfEUXNQ MonvbY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliaX6gZo91cCCmb4PlMUBidmRidHnt[U0h\GWyZX7k[Y51KG2jbn7ldi=> MU[yOlcxPzh6MR?=
K1  NV7qNGNWS2WubDDDfYNt\SCDc4PhfS=> NV7WV|ZyOjVyL{WwNE8yODByIH7N Mo\2O|IhcA>? NEmzcJpFVVOR Mlv0ZZJz\XO2czDj[YxtKGO7Y3zlJIF1KEdyL1exJJBp[XOn NX6zWIxFOjZ5MEe4PFE>
BCPAP MVvD[YxtKEO7Y3zlJGF{e2G7 NIXxPIwzPTBxNUCwM|ExODBibl2= MVq3NkBp MX;EUXNQ NH\pXHRienKnc4TzJINmdGxiY4njcIUh[XRiR{CvS|EheGijc3W= M2L3fFI3PzB5OEix
Hep3B M1\5OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkTlNE0yOCEQvF2= NXzTZodCPSCm M{fKd2ROW09? M4rGXmlEPTB;MD6wPEDPxE1? MY[yOlU4PTF4Nx?=
HCCLM3 NInXSVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml\HNE0yOCEQvF2= MVG1JIQ> MUTEUXNQ NHfRdVlKSzVyPUCuNVQh|ryP MWiyOlU4PTF4Nx?=
HuH7 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWDnclNWOC1zMDFOwG0> MljwOUBl MX\EUXNQ NXXw[Jp1UUN3ME2wMlIyKM7:TR?= MmixNlY2PzVzNke=
HepG2 M1HkTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MorNNE0yOCEQvF2= NGO1OJE2KGR? NIfvUGVFVVOR M2XF[2lEPTB;MD6zOEDPxE1? NXXhPVlEOjZ3N{WxOlc>
SMMC7721 NIL2fZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXmwMVExKM7:TR?= NWmxOmd5PSCm NWXDVWxwTE2VTx?= MlvpTWM2OD1yLkSxJO69VQ>? NIDie5YzPjV5NUG2Oy=>
BEL7402 NXvlXod7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH;TZWkxNTFyIN88US=> M{PRclUh\A>? NHrVXZZFVVOR NXzJcXQ6UUN3ME2wMlQ4KM7:TR?= M4X6dlI3PTd3MU[3
MHCC97H NELJVnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{Hi[FAuOTBizszN MlrROUBl NEfXTGpFVVOR MVXJR|UxRTBwNEGg{txO M2TiN|I3PTd3MU[3
Hep3B NXTXO3YyS2WubDDDfYNt\SCDc4PhfS=> M{TtZlAvOS9yLkWvNk42KM7:TR?= NHzqdGQ1QCCq NY\kUI46TE2VTx?= NUjTbFFGdGWjZIOgeI8h[SC|dXLzeIFvfGmjbDDhZ4N2dXWuYYTpc44hd2ZiSFPDJINmdGy|IHnuJJN2[i2JMTDwbIF{\cLi MnrFNlY2PzVzNke=
HCCLM3 MX;D[YxtKEO7Y3zlJGF{e2G7 NFjp[2cxNjFxMD61M|IvPSEQvF2= NFLoXpE1QCCq NGTBZoRFVVOR NFrzS|Ft\WGmczD0c{BiKHO3YoP0ZY51cWGuIHHjZ5VufWyjdHnvckBw\iCKQ1OgZ4VtdHNiaX6gd5VjNUdzIIDoZZNmyqB? MmnYNlY2PzVzNke=
Hep3B NX;ieW5nSXCxcITvd4l{KEG|c3H5 NWLmUZJIOC5zL{CuOU8zNjVizszN NEi4Z2E1QCCq NUTBS|hDTE2VTx?= M33JboFkfGm4YYTld{Bk[XOyYYPlMVMh[W6mIHPhd5Bie2VvOTDlfJBz\XO|aX;uJIFv\CCrbnT1Z4VlKFCDUmCgZ4xm[X[jZ3WgZZMhf2WubDDhd{BkgXSxY3jyc41mKGNicnXs[YF{\SCrboTvJJRp\SCleYTvdIxie21iZoLvcUBucXSxY3jvcoRzcWF? MmHNNlY2PzVzNke=
HCCLM3 NWPJdZNySXCxcITvd4l{KEG|c3H5 MmrPNE4yNzBwNT:yMlUh|ryP M4jnXlQ5KGh? Ml33SG1UVw>? MlH1ZYN1cX[jdHXzJINie3Cjc3WtN{BidmRiY3HzdIF{\S17IHX4dJJme3Orb36gZY5lKGmwZIXj[YQhWEGUUDDjcIVifmGpZTDhd{B4\WyuIHHzJIN6fG:laILvcYUh[yC{ZXzlZZNmKGmwdH:geIhmKGO7dH;wcIF{dSCocn;tJI1qfG:laH;u[JJq[Q>? MlviNlY2PzVzNke=
A549 NEf6PHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3faNFAvOS1zMDFOwG0> MWq3NkBp NXfyNGhtcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NUXVW|g3OjZ2MUWyNlU>
H157 M2CyRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3HsfVAvOS1zMDFOwG0> Mkm3O|IhcA>? NWXRXVBIcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MnqwNlY1OTV{MkW=
H1299 MkHZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWWwMlEuOTBizszN MmTKO|IhcA>? NHGxT|RqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MVqyOlQyPTJ{NR?=
A549 NUDYRYJVTnWwY4Tpc44hSXO|YYm= MoHPNU8zNjVxNTFOwG0> M2LBO|EzKGh? MnnjxsB4\WGtbImg[IVkemWjc3XkJGJkdC1{IHzleoVtew>? MnnnNlY1OTV{MkW=
H1299 NIj5eoRHfW6ldHnvckBCe3OjeR?= NUX2VnlZOS9{LkWvOUDPxE1? MUOxNkBp M{HBSOKhf2Wja3z5JIRm[3KnYYPl[EBD[2xvMjDs[ZZmdHN? M13IOFI3PDF3MkK1
H157 MlT2SpVv[3Srb36gRZN{[Xl? NXO0b3FTOS9{LkWvOUDPxE1? MoDRNVIhcA>? M{jjcYRm[3KnYYPl[EBFWjRiZYjwdoV{e2mxbh?= Mlz4NlY1OTV{MkW=
H1299 NIXSfXBHfW6ldHnvckBCe3OjeR?= M2rJNFEwOi53L{Wg{txO NFK5cFgyOiCq M4PnfYRm[3KnYYPl[EBFWjRiZYjwdoV{e2mxbh?= NVH0[nVZOjZ2MUWyNlU>
C8161 MYLD[YxtKF[rYXLpcIl1gSCDc4PhfS=> M3r5RlAuOiEQvF2= MVq0JIQ> NFzQWphFVVOR NXmzU4tx\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NXrvXXdWOjZ|OUeyNlM>
Mel285 M4[yPGNmdGxiVnnhZoltcXS7IFHzd4F6 NXXO[2h3OC1{IN88US=> MUW0JIQ> M2\DPWROW09? MV\k[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NULDPFRFOjZ|OUeyNlM>
Mel290 MofNR4VtdCCYaXHibYxqfHliQYPzZZk> M3XOS|AuOiEQvF2= M2r3SVQh\A>? M2nmbWROW09? NXHkOJU5\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy Mk\FNlY{QTd{MkO=
92.1 NUPDU3VKS2WubDDWbYFjcWyrdImgRZN{[Xl? NFr3UogxNTJizszN NYnveJl5PCCm MWPEUXNQ NVPodnk4\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NHfobZozPjN7N{KyNy=>
Omm1.3 NF\jZmhE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NIDnNmoxNTJizszN MUm0JIQ> M3noWGROW09? NEPIcm5l\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= NHrtUZMzPjN7N{KyNy=>
Mel202 MYXD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MmXaNE0zKM7:TR?= NWjEbJBXPCCm MlHISG1UVw>? NXvFdpV1\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy MmezNlY{QTd{MkO=
Mel270 M{H6UWNmdGxiVnnhZoltcXS7IFHzd4F6 MkTDNE0zKM7:TR?= NVP2eZJOPCCm MoDmSG1UVw>? MlvQ[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ MYiyOlM6PzJ{Mx?=
Omm1 NIG3eHVE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MXuwMVIh|ryP NEDic2k1KGR? M36zR2ROW09? NGjTRZBl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= MmPINlY{QTd{MkO=
92.1 MUPBdI9xfG:|aYOgRZN{[Xl? M33sclUxOCCwTR?= NVnxO2ZLPDhiaB?= Ml3xSG1UVw>? MXvpcoR2[2W|IHHwc5B1d3Orcx?= NHLjboozPjN7N{KyNy=>
Omm1.3 MV\BdI9xfG:|aYOgRZN{[Xl? NGL3[Y02ODBibl2= MkPJOFghcA>? NVPaN5RJTE2VTx?= NFzvfoRqdmS3Y3XzJIFxd3C2b4Ppdy=> M3X2SlI3Ozl5MkKz
92.1 Mmm0R4VtdCCFeXPs[UBCe3OjeR?= NVjNW4IyPTByIH7N NXm5VVJOOjRxNEivO|IhcA>? NFzSUYpFVVOR M4TsWYlv\HWlZYOgeIhmKGOnbHygZYNkfW23bHH0bY9vKGG2IIP1Zk1IOcLi MmXnNlY{QTd{MkO=
Omm1.3 MnmwR4VtdCCFeXPs[UBCe3OjeR?= NYHMbmRoPTByIH7N M4\2NlI1NzR6L{eyJIg> NULBN5dXTE2VTx?= NYX2Vm9HcW6mdXPld{B1cGViY3XscEBi[2O3bYXsZZRqd25iYYSgd5VjNUdzwrC= NF:5UY4zPjN7N{KyNy=>
A549 MULGeY5kfGmxbjDBd5NigQ>? NULwT3BvOTByL{SwNE8yODByIH7N NF3HT4IzPCCq M1HlbpVxemWpdXzheIV{KGGwZDDhZ5RqfmG2ZYOgV2lTXDF? NHzH[|IzPjJzMkG5PS=>
MCF-7 NUPifFVVTnWwY4Tpc44hSXO|YYm= NES3SmcyODBxNECwM|ExODBibl2= NGfmW5YzPCCq M2PBVJVxemWpdXzheIV{KGGwZDDhZ5RqfmG2ZYOgV2lTXDF? NUDKcI5OOjZ{MUKxPVk>
HEK293 MV;GeY5kfGmxbjDBd5NigQ>? NEjrW28yODBxNECwM|ExODBibl2= MoG0NlQhcA>? MW\1dJJm\3WuYYTld{BidmRiYXP0bZZifGW|IGPJVnQy NV7QNW1lOjZ{MUKxPVk>
858 MXLD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MUSwMVEh|ryP NHHnSYE2KGR? NVTCWYZGTE2VTx?= MWHk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NYjHO3JNOjZ{ME[zN|M>
DDR2L63V M3\GbWNmdGxiVnnhZoltcXS7IFHzd4F6 MX2wMVEh|ryP NG\JZmw2KGR? MmKxSG1UVw>? MXHk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? M2DMT|I3OjB4M{Oz
BE(2)-C NWTufYxnS2WubDDWbYFjcWyrdImgRZN{[Xl? NYTIXpBVOSEQvF2= MVuxMVQh\A>? NXXEXotS\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JJNq\26rZnnjZY51dHl? NH\WNJozPjB4N{S2OC=>
IMR-32 NV7FZXdFS2WubDDWbYFjcWyrdImgRZN{[Xl? MnXQNUDPxE1? MlG0NU01KGR? M{jvdIRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDzbYdvcW[rY3HueIx6 MlfGNlYxPjd2NkS=
JF MoGxR4VtdCCYaXHibYxqfHliQYPzZZk> NGfZO2gyKM7:TR?= MXyxMVQh\A>? MWjk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHlic3nncolncWOjboTsfS=> NUDmdWNMOjZyNke0OlQ>
BE(2)-M17 NIHNWZFE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NETZeZoyKM7:TR?= MVmxMVQh\A>? NHTB[o5l\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgd4lodmmoaXPhcpRtgQ>? MmrhNlYxPjd2NkS=
SK-N-SH MWnD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MmrtNUDPxE1? NILXSFYyNTRiZB?= NEHDUodl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgd4lodmmoaXPhcpRtgQ>? NXvMSZFrOjZyNke0OlQ>
SK-N-DZ  NHj4dGJE\WyuIG\pZYJqdGm2eTDBd5NigQ>? M32zU|Eh|ryP NF;uWIgyNTRiZB?= NG\V[FFl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgd4lodmmoaXPhcpRtgQ>? M2HnfFI3ODZ5NE[0
HMC-1.1  MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYO1MVUxODBibl2= M2Tq[lQ5KGh? Ml;CSG1UVw>? M4PJXIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MnLLNlYxPTV|MEO=
HMC-1.2 NVXXfodbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV7tW5p1PS13MECwJI5O NWDZfXN7PDhiaB?= MmrpSG1UVw>? M{T2OYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MYGyOlA2PTNyMx?=
ROSA KIT WT  NF\1d|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkfUOU02ODByIH7N M{LQRlQ5KGh? NE[3O3dFVVOR NHOzXFRqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MmS4NlYxPTV|MEO=
ROSA KIT D816V M2nMfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWO1MVUxODBibl2= MU[0PEBp MoG0SG1UVw>? NXvhVItxcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NILTbYYzPjB3NUOwNy=>
HMC-1.1  MnLSRZBweHSxc3nzJGF{e2G7 NGnuNFczODBvNUCwNEBvVQ>? MXm0PEBp MnH0SG1UVw>? MmPsbY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NELLWJYzPjB3NUOwNy=>
HMC-1.2 Mlj6RZBweHSxc3nzJGF{e2G7 M4jPV|IxOC13MECwJI5O M1TBPFQ5KGh? NXizdHFjTE2VTx?= NFnDb4FqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NYPRV2tDOjZyNUWzNFM>
ROSA KIT WT  M2\5Z2Fxd3C2b4Ppd{BCe3OjeR?= NWC2NHViOjByLUWwNFAhdk1? NX73[YNqPDhiaB?= MkDrSG1UVw>? MlfKbY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? Mor0NlYxPTV|MEO=
ROSA KIT D816V MWfBdI9xfG:|aYOgRZN{[Xl? M3HhTFIxOC13MECwJI5O NVPOO2sxPDhiaB?= MkjiSG1UVw>? M{LPSolv\HWlZYOgZ4VtdCCjcH;weI9{cXNiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MnzoNlYxPTV|MEO=
494H MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlLzO|IhcA>? MWLEUXNQ MnrSTWM2OD1yLkGyNuKyOC5yMESg{txO MnvONlU6PDR3Nk[=
493H MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MofhO|IhcA>? MYLEUXNQ MlPLTWM2OD1yLkC0O:KyOC5yMEmg{txO NG[zRWEzPTl2NEW2Oi=>
716H NGPHOnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnvUO|IhcA>? MV7EUXNQ NHSyZXRKSzVyPUCuNlEzyrFyLkCzOEDPxE1? NYHMS2hCOjV7NES1OlY>
148I MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVe3NkBp MoezSG1UVw>? MkjjTWM2OD1yLkK4OOKyOC5yM{Wg{txO NITuWGczPTl2NEW2Oi=>
98Sc M3TUSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3\WUVczKGh? NVTBS2FvTE2VTx?= NGfDcJRKSzVyPUCuNVE2yrFyLkCwOEDPxE1? NIXWOYszPTl2NEW2Oi=>
89R NGPScpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIHTd4E4OiCq M1nadmROW09? NXnuXFVnUUN3ME2wMlEzPsLzMD6wNFMh|ryP NH;LXYozPTl2NEW2Oi=>
494L M37meGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{DBOFczKGh? M1\SfmROW09? MX3JR|UxRTBwM{G3xtExNjBzMjFOwG0> MV:yOVk1PDV4Nh?=
493L NXX5bIh7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXS5V2hYPzJiaB?= NFntb5BFVVOR M121e2lEPTB;MD6wOVDDuTBwMEGxJO69VQ>? M4XMXVI2QTR2NU[2
148L NELtTG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVv6eXp1PzJiaB?= M2S3PGROW09? NVrBcFd1UUN3ME2wMlE1PsLzMD6wNVch|ryP MoflNlU6PDR3Nk[=
98L NHrjR2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWS3NkBp NIDFXXdFVVOR NHfVe4RKSzVyPUCuN|A6yrFyLkCyPUDPxE1? M1H0VlI2QTR2NU[2
OS17 NGDq[|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXG3NkBp MkG0SG1UVw>? MY\JR|UxRTBwMEe5xtExNjByMzFOwG0> MX6yOVk1PDV4Nh?=
OS9 MoPOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXPQ[5NSPzJiaB?= NV;5PFhRTE2VTx?= MnfqTWM2OD1yLkSwOuKyOC5yMkig{txO M4TuR|I2QTR2NU[2
MG63 NH;t[HJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWW3NkBp NXrLRZB2TE2VTx?= MXnJR|UxRTBwMUG0xtExNjB{NTFOwG0> M32zbVI2QTR2NU[2
SAOS2 NVnHWlliT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHfPVYE4OiCq NF3IVZZFVVOR NF;CS25KSzVyPUCuNlE4yrFyLkCwN{DPxE1? NUHWR3A3OjV7NES1OlY>
U2OS M4iyRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mnf5O|IhcA>? NETqWHNFVVOR MXnJR|UxRTBwMUm4xtExNjByODFOwG0> MUiyOVk1PDV4Nh?=
SJSA-1 MoPKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHjFOXA4OiCq NFrIZXpFVVOR MUnJR|UxRTBwMUCwxtExNjBzMDFOwG0> NH;hToMzPTl2NEW2Oi=>
494H NWjPdnNGSXCxcITvd4l{KEG|c3H5 NYDPbFFTOC5{NT:wMlUwOS5yIN88US=> NYnZe5FEOjRiaB?= NUDuNmI5TE2VTx?= M3rVTIlv[3KnYYPld{Bt\X[nbIOgc4Yh[2ynYY\l[EBk[XOyYYPlMVPDqA>? NXGyZW52OjV7NES1OlY>
148I NIPyOWxCeG:ydH;zbZMhSXO|YYm= M2faeVAvOjVxMD61M|EvOCEQvF2= MY[yOEBp MnK3SG1UVw>? NV3UU2Y4cW6lcnXhd4V{KGyndnXsd{Bw\iClbHXheoVlKGOjc4Dhd4UuO8Li M2XuZ|I2QTR2NU[2
OS17 NHHsZpVCeG:ydH;zbZMhSXO|YYm= NGeyOFgxNjJ3L{CuOU8yNjBizszN M1qzN|I1KGh? NFvvfpRFVVOR MnzibY5kemWjc3XzJIxmfmWuczDv[kBkdGWjdnXkJINie3Cjc3WtN:Kh MmH0NlU6PDR3Nk[=
494H Ml;pRZBweHSxc3nzJGF{e2G7 NFTNO4oy6oDLzszN MVG0PEBp MnrMSG1UVw>? M2eyWolv\HWlZYOgZ4VtdCCjcH;weI9{cXNic3nncolncWOjboTsfS=> MVGyOVk1PDV4Nh?=
148I NX\ZNXRNSXCxcITvd4l{KEG|c3H5 NXPCUnNlOeLCid88US=> NELPTHM1QCCq NHTa[4FFVVOR MlHVbY5lfWOnczDj[YxtKGGyb4D0c5NqeyC|aXfubYZq[2GwdHz5 M2HaR|I2QTR2NU[2
OS17 M4nnNWFxd3C2b4Ppd{BCe3OjeR?= MmDKNgKBkc7:TR?= MXS0PEBp M{DIbGROW09? MmDEbY5lfWOnczDj[YxtKGGyb4D0c5NqeyC|aXfubYZq[2GwdHz5 M{DnfFI2QTR2NU[2
MOLM13 M2nwN2Fxd3C2b4Ppd{BCe3OjeR?= MU[yOVAhdk1? NWHzSllnPDhiaB?= NYL6e5o1TE2VTx?= Mm\SbY5lfWOnczDzbYdvcW[rY3HueIx6KGGyb4D0c5NqeyClb4Ty[YF1dWWwdDD3bZRpKHG3aYrhdpRqdmmk M3yyPFI2ODV|OEK1
MV4-11  NFLzUlhCeG:ydH;zbZMhSXO|YYm= M4HHWVI2OCCwTR?= MkTnOFghcA>? NF\NR|NFVVOR MlrabY5lfWOnczDzbYdvcW[rY3HueIx6KGGyb4D0c5NqeyClb4Ty[YF1dWWwdDD3bZRpKHG3aYrhdpRqdmmk NV;WOGM1OjVyNUO4NlU>
MOLM13 MXTGeY5kfGmxbjDBd5NigQ>? MmjJNlUxKG6P MlXvNlQhcA>? NEH3U2pFVVOR M1HVeYVvcGGwY3XzJJF2cXqjcoTpcoljNWmwZIXj[YQhdW:{ZTDwNlEtKEKLTTygZY5lKGOuZXH2[YQhWEGUUB?= NU[yZ3p{OjVyNUO4NlU>
MV4-11  NX3qfYJwTnWwY4Tpc44hSXO|YYm= NWLKUIpsOjVyIH7N MnfwNlQhcA>? NUHER3RpTE2VTx?= MkjF[Y5p[W6lZYOgdZVqgmG{dHnubYIucW6mdXPl[EBud3KnIICyNUwhSkmPLDDhcoQh[2ynYY\l[EBRSVKS NH7KbYEzPTB3M{iyOS=>
MOLM13 M{DCcGFxd3C2b4Ppd{BCe3OjeR?= MnnUNlUxKG6P M1LvOVQ5KGh? M{Dr[WROW09? NHTESG9qdmS3Y3XzJJNq\26rZnnjZY51dHliYYDvdJRwe2m|IHPveJJm[XSvZX70JJdqfGhicH;uZZRqdmmk MnHONlUxPTN6MkW=
MV4-11  M2\YTWFxd3C2b4Ppd{BCe3OjeR?= M{nTNVI2OCCwTR?= NX;pTpo2PDhiaB?= MkLJSG1UVw>? NGrKbWhqdmS3Y3XzJJNq\26rZnnjZY51dHliYYDvdJRwe2m|IHPveJJm[XSvZX70JJdqfGhicH;uZZRqdmmk NIrySFQzPTB3M{iyOS=>
Hela MmDvR4VtdCCYaXHibYxqfHliQYPzZZk> M1u1flAuPTByIH7N MoqwO|IhcA>? NVXKNY9wTE2VTx?= M1vkV4Rm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= MoOwNlUxODl{OUW=
HBL-1 NHznc2VE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NIjWS3ExNTVyMDDuUS=> MkPYO|IhcA>? M4DsSWROW09? Mnvr[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NFXDUIIzPTByOUK5OS=>
HLY-1 Mn3qR4VtdCCYaXHibYxqfHliQYPzZZk> MXSwMVUxOCCwTR?= MlrNO|IhcA>? NGPGZnlFVVOR MUjk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MoPRNlUxODl{OUW=
OCI-Ly3 MkfhR4VtdCCYaXHibYxqfHliQYPzZZk> M{\aXlAuPTByIH7N MlXTO|IhcA>? MkjUSG1UVw>? MV;k[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NECwO2MzPTByOUK5OS=>
OCI-Ly10 NFXXPZRE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NUTEPHNpOC13MECgcm0> MUO3NkBp M2LidWROW09? MlPs[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ MVOyOVAxQTJ7NR?=
SU-DHL-4 M4fqcmNmdGxiVnnhZoltcXS7IFHzd4F6 NEHpdnoxNTVyMDDuUS=> NEDhRVI4OiCq NHfDOXBFVVOR NHnrZo9l\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= MWCyOVAxQTJ7NR?=
SU-DHL-5 MXXD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MnzJNE02ODBibl2= MWe3NkBp M4f6XGROW09? MlTN[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ MnvmNlUxODl{OUW=
SU-DHL-6 M2TVOWNmdGxiVnnhZoltcXS7IFHzd4F6 NWTsNm5JOC13MECgcm0> MnrvO|IhcA>? NWLnVmhQTE2VTx?= NHjPS2Zl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= M1;B[VI2ODB7Mkm1
SU-DHL-10 MYfD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NInNWVIxNTVyMDDuUS=> MkTTO|IhcA>? NYfZNndRTE2VTx?= M2rNdoRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= M360[FI2ODB7Mkm1
RC-K8 MnX5R4VtdCCYaXHibYxqfHliQYPzZZk> NH;SRoExNTVyMDDuUS=> NW\3U41kPzJiaB?= MWfEUXNQ MkXX[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NELze3MzPTByOUK5OS=>
OCI-Ly8 NEGzb5RE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NHPwOZQxNTVyMDDuUS=> MnPaO|IhcA>? MnnNSG1UVw>? NYPqc4VL\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NYq0PZVTOjVyMEmyPVU>
OCL-Ly18 MkLWR4VtdCCYaXHibYxqfHliQYPzZZk> MUCwMVUxOCCwTR?= NHvXPFc4OiCq MVPEUXNQ NEHlcVhl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= NF7Pc3gzPTByOUK5OS=>
OCI-Ly3 M3n3emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnntNVczNzJ3MD:1NFAhdk1? M3;ISVIwPyCm MXzEUXNQ MWrpcoR2[2W|IHPlcIwu[3mlbHWgZZJz\XO2IHH0JJN2[i2JMTD3bZRpKG2rbnntZYwh[2WubDDk[YF1cMLi NHvIRmMzPTByOUK5OS=>
OCI-Ly8 NFfCfHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX[xO|IwOjVyL{WwNEBvVQ>? M{H3OVIwPyCm NETSelBFVVOR MmjibY5lfWOnczDj[YxtNWO7Y3zlJIFzemW|dDDheEB{fWJvR{Gge4l1cCCvaX7pcYFtKGOnbHyg[IVifGkEoB?= NETESJQzPTByOUK5OS=>
SU-DHL-4 NHe4WpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGnCNVgyPzJxMkWwM|UxOCCwTR?= NVPXWoptOi95IHS= M3\NWWROW09? NEXsdoZqdmS3Y3XzJINmdGxvY4njcIUh[XK{ZYP0JIF1KHO3Yj3HNUB4cXSqIH3pcolu[WxiY3XscEBl\WG2aNMg M4D1XFI2ODB7Mkm1
SU-DHL-10 M3XsU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnHlNVczNzJ3MD:1NFAhdk1? M3TNd|IwPyCm M1jSW2ROW09? NFriS3NqdmS3Y3XzJINmdGxvY4njcIUh[XK{ZYP0JIF1KHO3Yj3HNUB4cXSqIH3pcolu[WxiY3XscEBl\WG2aNMg NFrpW5AzPTByOUK5OS=>
OCI-Ly3 NXXIZZVkSXCxcITvd4l{KEG|c3H5 NYTBdIJiOTd{L{K1NEBvVQ>? NWf3RWlLP2R? MWLEUXNQ NFfITIxqdmO{ZXHz[ZMh[2G|cHHz[U0{NzdiYXP0bZZqfHoEoIPp[45q\mmlYX70cJk> NH62XnAzPTByOUK5OS=>
OCI-Ly8 NWP0R2xUSXCxcITvd4l{KEG|c3H5 NWLW[|I4OTd{L{K1NEBvVQ>? NELTWY44\A>? MVvEUXNQ MYDpcoNz\WG|ZYOgZ4F{eGG|ZT2zM|ch[WO2aY\peJnDqHOrZ37p[olk[W62bIm= MorLNlUxODl{OUW=
SU-DHL-4 M3j5[WFxd3C2b4Ppd{BCe3OjeR?= MYmxO|IwOjVyIH7N NX\MOVhxP2R? M1O3XWROW09? MmPNbY5kemWjc3XzJINie3Cjc3WtN{84KGGldHn2bZR6yqC|aXfubYZq[2GwdHz5 NF36UWMzPTByOUK5OS=>
SU-DHL-10 Mn34RZBweHSxc3nzJGF{e2G7 NF\TdmcyPzJxMkWwJI5O M2D1R|dl MU\EUXNQ MlLRbY5kemWjc3XzJINie3Cjc3WtN{84KGGldHn2bZR6yqC|aXfubYZq[2GwdHz5 MUWyOVAxQTJ7NR?=

... Click to View More Cell Line Experimental Data

In vivo (+)-JQ1 (50 mg/kg) inhibits tumors growth in mice with NMC 797 xenografts. (+)-JQ1 (50 mg/kg) results in effacement of NUT nuclear speckles in mice with NMC 797 xenografts, consistent with competitive binding to nuclear chromatin. (+)-JQ1 (50 mg/kg) induces strong (grade 31) keratin expression in NMC 797 xenografts. (+)-JQ1 (50 mg/kg) promotes differentiation, tumor regression and prolonged survival in mice models of NMC xenografts. [1] (+)-JQ1 (50 mg/kg) results in a significant prolongation in overall survival of SCID-beige mice orthotopically xenografted after intravenous injection with MM.1S-luc+ cells compared to vehicle-treated animals. [2] (+)-JQ1 (50 mg/kg i.p.) leads to a highly significant increase in survival of mice bearing Raji xenografts. [3]

Protocol

Cell Research
+ Expand
  • Cell lines: MC 11060 cells
  • Concentrations: ~500 nM
  • Incubation Time: 48 hours
  • Method:

    Cells are seeded into white, 384-well microtiter plates at 500 cells per well in a total volume of 50 μL media. The 797, TT and TE10 cells are grown in DMEM containing 1% penicillin/streptomycin and 10% FBS. The Per403 cells are grown in DMEM containing 1 % penicillin/streptomycin and 20% FBS. Patient-derived NMC 11060 cells are grown in RPMI with 10% FBS and 1% penicillin/streptomycin. (+)-JQ1 is delivered to microtiter assay plates by robotic pin transfer. Following a 48 hours incubation at 37℃, cells are lysed and wells are assessed for total ATP content using a commercial proliferation assay. Replicate measurements are analyzed with respect to dose and estimates of IC50 are calculated by logistic regression (GraphPad Prism).


    (Only for Reference)
Animal Research
+ Expand
  • Animal Models: Mice bearing NMC 797 xenografts
  • Formulation: 5% DMSO in 5% dextrose
  • Dosages: 50 mg/kg
  • Administration: intraperitoneal injection
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 91 mg/mL (199.12 mM) warming
Ethanol 91 mg/mL (199.12 mM)
Water <1 mg/mL
In vivo 2% DMSO+30% PEG 300+5% Tween 80+ddH2O 5mg/mL

* 1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 456.99
Formula

C23H25ClN4O2S

CAS No. 1268524-70-4
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Epigenetic Reader Domain Signaling Pathway Map

Epigenetic Reader Domain Inhibitors with Unique Features

Tags: buy (+)-JQ1 | (+)-JQ1 supplier | purchase (+)-JQ1 | (+)-JQ1 cost | (+)-JQ1 manufacturer | order (+)-JQ1 | (+)-JQ1 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID